Bayer's healthcare sales up 9% in first quarter:
This article was originally published in Clinica
Germany-based Bayer saw healthcare sales, which include diagnostics, increase 9% to DM 3.1 billion ($1.8 billion) in the first quarter of 1997. The company says its diagnostics business experienced "good gains". Bayer's Agfa division, which includes medical imaging systems, reported sales of DM 1.8 billion, up 3%. The company's total sales rose 8% to DM 13.2 billion.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.